Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvectis Pharma (NVCT) Share-based Compensation (2021 - 2026)

Nuvectis Pharma has reported Share-based Compensation over the past 6 years, most recently at $1.8 million for Q1 2026.

  • Quarterly results put Share-based Compensation at $1.8 million for Q1 2026, up 35.23% from a year ago — trailing twelve months through Mar 2026 was $5.1 million (up 42.03% YoY), and the annual figure for FY2025 was $6.0 million, up 24.17%.
  • Share-based Compensation reached $1.8 million in Q1 2026 per NVCT's latest filing, up from $1.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.8 million in Q1 2026 and bottomed at $156000.0 in Q1 2022.
  • Median Share-based Compensation over the past 5 years was $900000.0 (2025), compared with a mean of $875941.2.
  • The largest annual shift saw Share-based Compensation plummeted 77.78% in 2022 before it soared 798.72% in 2023.
  • Over 5 years, Share-based Compensation stood at $482000.0 in 2022, then surged by 153.11% to $1.2 million in 2023, then decreased by 6.48% to $1.1 million in 2024, then grew by 29.36% to $1.5 million in 2025, then rose by 25.34% to $1.8 million in 2026.
  • Business Quant data shows Share-based Compensation for NVCT at $1.8 million in Q1 2026, $1.5 million in Q4 2025, and $900000.0 in Q3 2025.